Boris Kubuschok

Boris Kubuschok

Auto-generated profile, based on publicly available information

Boris Kubuschok

Department of Internal Medicine II (Hematology/Oncology) and Comprehensive Cancer Center Augsburg, CCC Alliance WERA and Bavarian Cancer Research Center (BZKF), Universitätsklinikum Augsburg, Augsburg, Germany

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 October 2023 in Nature Communications
Verified
Journal Article
Open access
PDF file
MPMaria Pouyiourou
Maria Pouyiourou
BKBianca N. Kraft
Bianca N. Kraft
TWTimothy Wohlfromm
Timothy Wohlfromm
MSMichael Stahl
Michael Stahl
BKBoris Kubuschok
Boris Kubuschok
AKAlwin Krämer
Alwin Krämer
Cancer of unknown primary has a dismal prognosis, especially following failure of platinum-based chemotherapy. 10-20% of patients have a high tumor mutational burden (TMB), which predicts response to immunotherapy in many cancer types. In this prospective, non-randomized, open-label, multicenter Phase II trial (EudraCT 2018-004562-33; NCT04131621), patients relapsed or refractory after platinum-based chemotherapy received nivolumab and ipilimumab following TMBhigh vs. TMBlow stratification. Progression-free survival (PFS) represented the primary endpoint; overall survival (OS), response rates, duration of clinical benefit and safety were the secondary endpoints. The trial was prematurely terminated in March 2021 before reaching the preplanned sample size (n = 194). Among 31 evaluable patients, 16% had a high TMB ( > 12 mutations/Mb). Overall response rate was 16% (95% CI 6-34%), with 7.7% (95% CI 1-25%) vs. 60% (95% CI 15-95%) in TMBlow and TMBhigh, respectively. Although the primary endpoint was not met, high TMB was associated with better median PFS (18.3 vs. 2.4 months) and OS (18.3 vs. 3.6 months). Severe immune-related adverse events were reported in 29% of cases. Assessing on-treatment dynamics of circulating tumor DNA using combined targeted hotspot mutation and shallow whole genome sequencing as part of a predefined exploratory analysis identified patients benefiting from immunotherapy irrespective of initial radiologic response.

1 May 2002 in Human Gene Therapy
Verified
Journal Article
Closed access
BKBoris Kubuschok
Boris Kubuschok
RSRudolf Schmits
Rudolf Schmits
FHFrank Hartmann
Frank Hartmann
CCChristiane Cochlovius
Christiane Cochlovius
RBRainer Breit
Rainer Breit
MPMichael Pfreundschuh
Michael Pfreundschuh
Spontaneous Epstein-Barr virus (EBV)-transformed lymphoblastoid cell lines (SP-LCLs) can be easily obtained from latently EBV-infected cancer patients and used as a source of antigen-presenting cells (APCs) for immunotherapy. Using point-mutated (codon 12) p21ras (muRas) as a model tumor antigen, we evaluated the practicability of using genetically modified SP-LCLs as cancer vaccines for patients with pancreatic cancer expressing mutated Ras (muRas). The repeated stimulation of peripheral blood mononuclear cells (PBMCs) from patients with muRas-LCLs elicited a strong, muRas-specific T cell response. A significant cytotoxic activity against EBV virus proteins or components of the expression vector was not observed. The T cells were able to recognize naturally presented muRas, as shown by their cytotoxicity against muRas (Gly-12 to Val-12 or Asp-12)-expressing tumor cells. The T cell response was mainly MHC class I restricted, and peptides containing amino acids 5 to 14 of muRas-Val-12 and muRas-Asp-12 were identified as immunogenic peptides for HLA-A2. In contrast to the situation in patients with putatively muRas-primed T cells, muRas-LCLs were not able to prime naive T lymphocytes from healthy controls. Vaccination of a pancreatic cancer patient with muRas-LCL induced muRas-specific T cells in PBMCs after 4 weeks. We conclude that genetically modified muRas-LCLs can efficiently present tumor antigens to the immune system and induce antigen-specific cytotoxic T cell responses in vitro and in vivo.

20 June 2024 in Annals of Hematology
Verified
Journal Article
Open access
PDF file
BKBoris Kubuschok
Boris Kubuschok
BOBurkhard Otremba
Burkhard Otremba
MWManfred Welslau
Manfred Welslau
JTJulian Topaly
Julian Topaly
TWThomas Wolff
Thomas Wolff
TFTobias Foierl
Tobias Foierl
Health-related quality of life (HRQoL) data are important indicators of health status in patients with lymphoma. The objective of this analysis was to assess the impact of treatment with Sandoz rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) on HRQoL in treatment-naïve adult patients with diffuse large B-cell lymphoma (DLBCL) included in the prospective, real-world REFLECT study. REFLECT is the first prospective study to assess HRQoL in patients with DLBCL treated with a rituximab biosimilar. HRQoL was assessed via the patient-reported European Organization for Research and Treatment of Cancer Core Quality of Life questionnaire at baseline, mid-treatment (month 3), end of treatment (month 6), and follow-up (months 9 and 12). Subgroup analyses were performed to evaluate the influence of baseline characteristics on HRQoL, and associations between baseline HRQoL and treatment response. HRQoL was assessed in 169 patients. Mean global health status score remained stable from baseline (54.8) to mid-treatment (month 3; 54.7), before steadily improving through to end of treatment (month 6; 61.4), and follow-up month 9 (64.9) and month 12 (68.8). Similar trends were observed across most functional and symptom subscales. Higher cognitive, physical, or role functioning, and less appetite loss, diarrhea, fatigue, or pain at baseline, were all associated with an improved likelihood of reaching a complete versus partial response at the end of treatment. Overall, these findings confirm the HRQoL benefits of R-CHOP therapy in treatment-naïve adult patients with DLBCL, and suggest that baseline HRQoL may be predictive of treatment response.

1 September 2021 in Annals of Oncology
Verified
Journal Article
Closed access
PDF file
HMH. Müller-Huesmann
H. Müller-Huesmann
EHE. von der Heyde
E. von der Heyde
DHD. Hahn
D. Hahn
CLChristine Langer
Christine Langer
BKB. Kubuschok
B. Kubuschok
ADAndreas Dietz
Andreas Dietz

21 February 2024 in Die Onkologie
Verified
Journal Article
Closed access
PDF file
BKBoris Kubuschok
Boris Kubuschok
RCRainer Claus
Rainer Claus
MSMichael Stahl
Michael Stahl